Adrenergic beta 2-selective blocker in isoprenaline-enhanced essential tremor.
A beta 2-selective adrenergic-receptor-blocking drug, ICI 118.551, 150 mg/day, prevented almost as effectively as the nonselective antagonist propranolol, 240 mg/day, the isoprenaline enhancement of essential tremor amplitude.
Teräväinen
H
H
Department of Neurology, University of Helsinki, Finland.
Huttunen
J
J
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007545:Isoproterenol; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use; D011674:Pulse / Q000187:drug effects; D014202:Tremor / Q000188:drug therapy*
D011412:Propanolamines; C026777:ICI 118551; D011433:Propranolol; D007545:Isoproterenol